TISIDB

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Golgi apparatus membrane Single-pass type II membrane protein
Domain	PF02485 Core-2/I-Branching enzyme
Function	Glycosyltransferase that can synthesize all known mucin beta 6 N-acetylglucosaminides. Mediates core 2 and core 4 O-glycan branching, 2 important steps in mucin-type biosynthesis. Has also I-branching enzyme activity by converting linear into branched poly-N-acetyllactosaminoglycans, leading to introduce the blood group I antigen during embryonic development.

> Gene Ontology [ TOP ]
Biological Process	GO:0001655 urogenital system development GO:0001822 kidney development GO:0002250 adaptive immune response GO:0002251 organ or tissue specific immune response GO:0002377 immunoglobulin production GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002385 mucosal immune response GO:0002426 immunoglobulin production in mucosal tissue GO:0002440 production of molecular mediator of immune response GO:0002443 leukocyte mediated immunity GO:0002449 lymphocyte mediated immunity GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains GO:0006486 protein glycosylation GO:0006493 protein O-linked glycosylation GO:0007586 digestion GO:0009100 glycoprotein metabolic process GO:0009101 glycoprotein biosynthetic process GO:0016064 immunoglobulin mediated immune response GO:0016266 O-glycan processing GO:0019724 B cell mediated immunity GO:0022600 digestive system process GO:0043413 macromolecule glycosylation GO:0050892 intestinal absorption GO:0060993 kidney morphogenesis GO:0070085 glycosylation GO:0072001 renal system development
Molecular Function	GO:0003829 beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity GO:0008109 N-acetyllactosaminide beta-1,6-N-acetylglucosaminyltransferase activity GO:0008194 UDP-glycosyltransferase activity GO:0008375 acetylglucosaminyltransferase activity GO:0016757 transferase activity, transferring glycosyl groups GO:0016758 transferase activity, transferring hexosyl groups GO:0047225 acetylgalactosaminyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00512 Mucin type O-Glycan biosynthesis hsa01100 Metabolic pathways
Reactome	R-HSA-392499: Metabolism of proteins R-HSA-5173105: O-linked glycosylation R-HSA-913709: O-linked glycosylation of mucins R-HSA-597592: Post-translational protein modification

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between GCNT3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of GCNT3 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of GCNT3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.242	0.46
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.367	0.531
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.682	0.185
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-1.023	0.158
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-1.116	0.327
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.908	0.484
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.423	0.626
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.185	0.906
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.9	0.556
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.471	0.731
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.651	0.751
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.97	0.0104

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of GCNT3 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	4.1	10.7	0.0828
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	5.1	9.7	0.199
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	9.5	11.8	-2.3	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	18.2	-10.5	0.576
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	0	7.9	0.26
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GCNT3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GCNT3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GCNT3. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GCNT3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of GCNT3 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between GCNT3 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	GCNT3
Name	glucosaminyl (N-acetyl) transferase 3, mucin type
Aliases	C2GnT-M; C2/4GnT; C2GnT2; C24GNT; C2GNTM; GNTM; C2GnT-mucin type; beta1,6-N-acetylglucosaminyltransferase-M; ......
Chromosomal Location	15q22
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting GCNT3 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse GCNT3